Sheikhah Fahad Aldossari

Dr. Sheikhah Fahad Aldossari


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
AAAbdulmajeed Alshabanat
Abdulmajeed Alshabanat
MAMaha Alrabiah
Maha Alrabiah
AZAmerah Mansour Bin Zuair
Amerah Mansour Bin Zuair
SASheikhah Fahad Aldossari
Sheikhah Fahad Aldossari
RARand Alhumaidi
Rand Alhumaidi
Background: SCD poses a significant healthcare burden. Understanding the factors contributing to high healthcare utilization and readmissions is crucial for improving the quality of care provided. Methods: This retrospective comparative observational study was conducted at King Saud University Medical City and included 160 SCD patients. A comparison was made between patients with no readmission and patients with at least one 30-day readmission. Another comparison was done between high healthcare-utilizing patients and low healthcare-utilizing patients. A regression model for 30-day readmission prediction was created. Results: Readmission was significantly higher in patients using opioids, following up with pain clinics, and having a history of AVN (p= 0.002, p=0.028 and p=0.025 respectively). Higher healthcare utilization was associated with older age, smoking, use of opioids and GABA analogs, and psychiatric illnesses, including depression, substance use disorder, and anxiety. Predictors of 30-day readmission were hydroxyurea use (odds ratio, 2.819 [95% CI,1.082 to 7.34], p = 0.034), follow-up with pain management clinics (odds ratio, 2.248 [95% CI,1.547 to 3.266], p = 0.001), and SCD genotype (SS genotype) (odds ratio, 1.754 [95% CI,1.012 to 3.042], p = 0.045). Using the Paracetamol/Codeine combination significantly reduced the likelihood of readmission within 30 days of discharge. Conclusion: This study identified factors associated with 30-day readmission rate and high healthcare utilization among SCD patients. Strategies to reduce readmissions may include specialized SCD clinics, educational programs for patients, improved physician awareness of mental health screening, and further research on the impact of opioid use. Limitations include retrospective nature, single-center design, reliance on self-reported data, and exclusion of critically ill patients. However, despite the limitations, this study could lay a foundation for future projects aiming to optimize care and outcomes for patients living with SCD.

1 August 2025 in International Medical Case Reports Journal
Verified
Journal Article
Open access
PDF file
BABashair Fahad Aldossari
Bashair Fahad Aldossari
SASheikhah Fahad Aldossari
Sheikhah Fahad Aldossari
A 7-year-old boy presented with new-onset type one diabetes mellitus (T1DM) and moderate diabetic ketoacidosis (DKA). The patient presented with polyuria, polydipsia, and weight loss along with reduced activity and excessive sleepiness. Initial blood tests revealed elevated blood glucose levels, high anion-gap metabolic acidosis, and ketonuria. The patient was treated with fluid resuscitation, insulin infusion, and electrolyte replacement, which resolved within three days. During medication reconciliation, the patient was administered empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, by a family member without medical supervision. This case highlights the challenges in managing pediatric diabetes, potential risks of unauthorized medication use, and need for comprehensive family education in diabetes care. This also raises questions regarding the safety and benefits of SGLT2 inhibitors in children under 10 years of age with type 1 diabetes mellitus, an area that requires further research.